Drug intelligence / Profile preview

KIN-201

Development stage: Preclinical
Lead developer: Kinimmune
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intratumoral

Overview

KIN-201 is an engineered cytokine (part of Kinimmune's Kinetokines platform) currently in the lead optimization stage of development for the treatment of solid tumors. Developed by Kinimmune, KIN-201 is designed for localized (intratumoral) administration to concentrate immune activation within the tumor microenvironment, thereby potentiating localized antitumor immune responses while minimizing systemic exposure and associated toxicities. The specific molecular target of KIN-201 remains undisclosed.

Beyond the preview

Go deeper on KIN-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIN-201.

Explore the full profile